Pevion Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pevion Biotech Ltd.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2014.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.
Pevion Biotech has appointed the former president of Sanofi-Pasteur MSD, Didier Hoch, to its board of directors. Mr Hoch served in the president role at Sanofi-Pasteur MSD from 2000-10, and has previously worked as vice-president Africa & Middle East at Aventis Pharma International and deputy general manager at Rhône-Poulenc Rorer France. Pevion is a Swiss vaccine company developing vaccines based on its virosome technology.
- Large Molecule